Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.

Miguel MartinElgene LimMariana Chavez Mac Gregor Aditya Bardia Jiong WuQingyuan ZhangZbigniew Nowecki Felipe José Silva Melo Cruz Rustem Safin Sung-Bae KimChristian SchemAlberto J MonteroSarah KhanReeti BandyopadhyayHeather M MooreMahesh ShivhareMonika PatreJorge MartinalboLaura RoncoroniPablo Diego Pérez-MorenoJoo Hyuk Sohnnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.

Keyphrases

phase ii
estrogen receptor
open label
clinical trial
double blind
placebo controlled
phase iii
electronic health record
big data
risk assessment
machine learning
data analysis
young adults
smoking cessation
deep learning
cell therapy
childhood cancer